Condition
Gastritis, Atrophic
Total Trials
6
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Unknown4
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05238181Unknown
Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis
NCT04296513CompletedPrimary
Diagnosis of Gastritis, H. Pylori Infection and Atrophic Gastritis in Dyspeptic Patients
NCT02114411UnknownPrimary
Gastropanel for Gastric Atrophy and Cancer Risk Assessment
NCT02915393UnknownPrimary
System Biology of Spleen Deficiency Syndrome
NCT02457624Unknown
Gastric Cancer Screening Quality Improvement System Establishment
NCT02524262Phase 2CompletedPrimary
L-cysteine Prevents Stomach Exposure to Carcinogenic Acetaldehyde
Showing all 6 trials